nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—acquired immunodeficiency syndrome—sarcoma	0.546	1	CtDrD
Lamivudine—ABCC3—Vincristine—sarcoma	0.0272	0.0837	CbGbCtD
Lamivudine—ABCC1—Dactinomycin—sarcoma	0.0271	0.0834	CbGbCtD
Lamivudine—SLC22A3—Vincristine—sarcoma	0.0256	0.0787	CbGbCtD
Lamivudine—ABCC3—Etoposide—sarcoma	0.0249	0.0767	CbGbCtD
Lamivudine—ABCC1—Mitoxantrone—sarcoma	0.0243	0.0747	CbGbCtD
Lamivudine—ABCC1—Epirubicin—sarcoma	0.0196	0.0604	CbGbCtD
Lamivudine—ABCG2—Dactinomycin—sarcoma	0.0182	0.0558	CbGbCtD
Lamivudine—ABCC3—Doxorubicin—sarcoma	0.017	0.0523	CbGbCtD
Lamivudine—ABCC1—Vincristine—sarcoma	0.0167	0.0514	CbGbCtD
Lamivudine—ABCG2—Mitoxantrone—sarcoma	0.0162	0.05	CbGbCtD
Lamivudine—ABCC1—Etoposide—sarcoma	0.0153	0.0471	CbGbCtD
Lamivudine—ABCC2—Vincristine—sarcoma	0.0124	0.038	CbGbCtD
Lamivudine—ABCC2—Etoposide—sarcoma	0.0113	0.0348	CbGbCtD
Lamivudine—ABCG2—Vincristine—sarcoma	0.0112	0.0344	CbGbCtD
Lamivudine—ABCC1—Doxorubicin—sarcoma	0.0104	0.0321	CbGbCtD
Lamivudine—ABCG2—Etoposide—sarcoma	0.0102	0.0315	CbGbCtD
Lamivudine—ABCC2—Doxorubicin—sarcoma	0.00773	0.0238	CbGbCtD
Lamivudine—ABCG2—Doxorubicin—sarcoma	0.00699	0.0215	CbGbCtD
Lamivudine—ABCB1—Dactinomycin—sarcoma	0.00655	0.0201	CbGbCtD
Lamivudine—ABCB1—Mitoxantrone—sarcoma	0.00586	0.018	CbGbCtD
Lamivudine—ABCB1—Vincristine—sarcoma	0.00403	0.0124	CbGbCtD
Lamivudine—ABCB1—Etoposide—sarcoma	0.00369	0.0114	CbGbCtD
Lamivudine—ABCB1—Doxorubicin—sarcoma	0.00252	0.00775	CbGbCtD
Lamivudine—PGK1—Glycolysis—ENO2—sarcoma	0.0014	0.0666	CbGpPWpGaD
Lamivudine—PGK1—hematopoietic system—sarcoma	0.00127	0.0314	CbGeAlD
Lamivudine—PGK1—Gluconeogenesis—ENO2—sarcoma	0.00125	0.0596	CbGpPWpGaD
Lamivudine—PGK1—connective tissue—sarcoma	0.00122	0.0303	CbGeAlD
Lamivudine—NME1-NME2—hematopoietic system—sarcoma	0.00115	0.0286	CbGeAlD
Lamivudine—PGK1—skin of body—sarcoma	0.0011	0.0273	CbGeAlD
Lamivudine—NT5C—hematopoietic system—sarcoma	0.00107	0.0265	CbGeAlD
Lamivudine—PCYT1A—hematopoietic system—sarcoma	0.001	0.0249	CbGeAlD
Lamivudine—PGK1—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.001	0.0478	CbGpPWpGaD
Lamivudine—PCYT1A—connective tissue—sarcoma	0.000967	0.024	CbGeAlD
Lamivudine—PGK1—uterus—sarcoma	0.000958	0.0237	CbGeAlD
Lamivudine—PGK1—Glycolysis and Gluconeogenesis—ENO2—sarcoma	0.000868	0.0413	CbGpPWpGaD
Lamivudine—PCYT2—testis—sarcoma	0.000809	0.0201	CbGeAlD
Lamivudine—NT5C—uterus—sarcoma	0.000809	0.0201	CbGeAlD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00079	0.0376	CbGpPWpGaD
Lamivudine—PCYT2—liver—sarcoma	0.000765	0.019	CbGeAlD
Lamivudine—NT5C—lymphoid tissue—sarcoma	0.000754	0.0187	CbGeAlD
Lamivudine—NME2—embryo—sarcoma	0.000709	0.0176	CbGeAlD
Lamivudine—NT5C—tendon—sarcoma	0.000708	0.0176	CbGeAlD
Lamivudine—NME1—Regulation of CDC42 activity—PLCG1—sarcoma	0.000703	0.0335	CbGpPWpGaD
Lamivudine—PGK1—testis—sarcoma	0.000695	0.0172	CbGeAlD
Lamivudine—NME1—hematopoietic system—sarcoma	0.000672	0.0167	CbGeAlD
Lamivudine—PGK1—liver—sarcoma	0.000657	0.0163	CbGeAlD
Lamivudine—CMPK1—hematopoietic system—sarcoma	0.000647	0.0161	CbGeAlD
Lamivudine—NME1—connective tissue—sarcoma	0.000647	0.016	CbGeAlD
Lamivudine—PGK1—Glucose metabolism—ENO2—sarcoma	0.000645	0.0307	CbGpPWpGaD
Lamivudine—NME2—hematopoietic system—sarcoma	0.000633	0.0157	CbGeAlD
Lamivudine—CMPK1—connective tissue—sarcoma	0.000623	0.0155	CbGeAlD
Lamivudine—NME1-NME2—liver—sarcoma	0.000598	0.0148	CbGeAlD
Lamivudine—NT5C—testis—sarcoma	0.000587	0.0145	CbGeAlD
Lamivudine—NME1—skin of body—sarcoma	0.000584	0.0145	CbGeAlD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—NPM1—sarcoma	0.000581	0.0277	CbGpPWpGaD
Lamivudine—PGK1—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000579	0.0276	CbGpPWpGaD
Lamivudine—CMPK1—smooth muscle tissue—sarcoma	0.00057	0.0141	CbGeAlD
Lamivudine—CMPK1—skin of body—sarcoma	0.000563	0.014	CbGeAlD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000558	0.0266	CbGpPWpGaD
Lamivudine—NT5C—liver—sarcoma	0.000555	0.0138	CbGeAlD
Lamivudine—PCYT1A—testis—sarcoma	0.00055	0.0137	CbGeAlD
Lamivudine—PCYT1A—liver—sarcoma	0.00052	0.0129	CbGeAlD
Lamivudine—NME1—uterus—sarcoma	0.000507	0.0126	CbGeAlD
Lamivudine—CMPK1—cardiac atrium—sarcoma	0.000492	0.0122	CbGeAlD
Lamivudine—CMPK1—uterus—sarcoma	0.000489	0.0121	CbGeAlD
Lamivudine—ABCC4—Ectoderm Differentiation—PTPRB—sarcoma	0.00048	0.0228	CbGpPWpGaD
Lamivudine—NME1—lymphoid tissue—sarcoma	0.000473	0.0117	CbGeAlD
Lamivudine—DCK—Doxorubicin—Epirubicin—sarcoma	0.000464	0.519	CbGdCrCtD
Lamivudine—NME1-NME2—lymph node—sarcoma	0.000459	0.0114	CbGeAlD
Lamivudine—CMPK1—lymphoid tissue—sarcoma	0.000456	0.0113	CbGeAlD
Lamivudine—NME2—lymphoid tissue—sarcoma	0.000445	0.011	CbGeAlD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—NPM1—sarcoma	0.000441	0.021	CbGpPWpGaD
Lamivudine—NME1—bone marrow—sarcoma	0.000431	0.0107	CbGeAlD
Lamivudine—DCK—Epirubicin—Doxorubicin—sarcoma	0.00043	0.481	CbGdCrCtD
Lamivudine—NT5C—lymph node—sarcoma	0.000425	0.0105	CbGeAlD
Lamivudine—CMPK1—bone marrow—sarcoma	0.000415	0.0103	CbGeAlD
Lamivudine—DCK—myometrium—sarcoma	0.000375	0.00931	CbGeAlD
Lamivudine—NME1—testis—sarcoma	0.000368	0.00913	CbGeAlD
Lamivudine—DCK—embryo—sarcoma	0.000361	0.00895	CbGeAlD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—IGF1R—sarcoma	0.00036	0.0171	CbGpPWpGaD
Lamivudine—CMPK1—testis—sarcoma	0.000355	0.0088	CbGeAlD
Lamivudine—NME1—liver—sarcoma	0.000348	0.00863	CbGeAlD
Lamivudine—NME2—testis—sarcoma	0.000347	0.0086	CbGeAlD
Lamivudine—DCK—seminal vesicle—sarcoma	0.000339	0.00841	CbGeAlD
Lamivudine—CMPK1—liver—sarcoma	0.000335	0.00832	CbGeAlD
Lamivudine—NME2—liver—sarcoma	0.000328	0.00813	CbGeAlD
Lamivudine—DCK—hematopoietic system—sarcoma	0.000322	0.00799	CbGeAlD
Lamivudine—PGK1—HIF-2-alpha transcription factor network—VEGFA—sarcoma	0.000319	0.0152	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—PLCG1—sarcoma	0.000316	0.015	CbGpPWpGaD
Lamivudine—ABCC3—hematopoietic system—sarcoma	0.000309	0.00765	CbGeAlD
Lamivudine—SLC22A3—myometrium—sarcoma	0.000306	0.00759	CbGeAlD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000299	0.0142	CbGpPWpGaD
Lamivudine—SLC22A3—embryo—sarcoma	0.000294	0.0073	CbGeAlD
Lamivudine—SLC22A3—seminal vesicle—sarcoma	0.000276	0.00685	CbGeAlD
Lamivudine—NME1—lymph node—sarcoma	0.000267	0.00662	CbGeAlD
Lamivudine—SLC22A3—hematopoietic system—sarcoma	0.000263	0.00652	CbGeAlD
Lamivudine—CMPK1—lymph node—sarcoma	0.000257	0.00638	CbGeAlD
Lamivudine—ABCC4—hematopoietic system—sarcoma	0.000255	0.00632	CbGeAlD
Lamivudine—ABCC1—myometrium—sarcoma	0.000253	0.00627	CbGeAlD
Lamivudine—SLC22A3—connective tissue—sarcoma	0.000253	0.00627	CbGeAlD
Lamivudine—NME2—lymph node—sarcoma	0.000251	0.00623	CbGeAlD
Lamivudine—DCK—cardiac atrium—sarcoma	0.000245	0.00607	CbGeAlD
Lamivudine—DCK—uterus—sarcoma	0.000243	0.00604	CbGeAlD
Lamivudine—ABCC3—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000238	0.0114	CbGpPWpGaD
Lamivudine—SLC22A3—smooth muscle tissue—sarcoma	0.000231	0.00574	CbGeAlD
Lamivudine—PGK1—Carbohydrate metabolism—ENO2—sarcoma	0.000229	0.0109	CbGpPWpGaD
Lamivudine—ABCC1—seminal vesicle—sarcoma	0.000229	0.00567	CbGeAlD
Lamivudine—DCK—lymphoid tissue—sarcoma	0.000227	0.00563	CbGeAlD
Lamivudine—NME1—E-cadherin signaling in the nascent adherens junction—CCND1—sarcoma	0.000225	0.0107	CbGpPWpGaD
Lamivudine—ABCC4—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000224	0.0107	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—PDGFRB—sarcoma	0.000224	0.0107	CbGpPWpGaD
Lamivudine—NME1—E-cadherin signaling in the nascent adherens junction—CTNNB1—sarcoma	0.000223	0.0106	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000215	0.0102	CbGpPWpGaD
Lamivudine—DCK—tendon—sarcoma	0.000213	0.00529	CbGeAlD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00021	0.01	CbGpPWpGaD
Lamivudine—ABCG2—myometrium—sarcoma	0.000209	0.00519	CbGeAlD
Lamivudine—DCK—bone marrow—sarcoma	0.000207	0.00512	CbGeAlD
Lamivudine—NME1—E-cadherin signaling in the nascent adherens junction—SRC—sarcoma	0.000202	0.0096	CbGpPWpGaD
Lamivudine—ABCC4—Ectoderm Differentiation—PAX3—sarcoma	0.000199	0.00948	CbGpPWpGaD
Lamivudine—ABCC4—uterus—sarcoma	0.000192	0.00477	CbGeAlD
Lamivudine—ABCG2—seminal vesicle—sarcoma	0.000189	0.00469	CbGeAlD
Lamivudine—ABCC3—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000189	0.00898	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000188	0.00894	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—KDR—sarcoma	0.000185	0.00883	CbGpPWpGaD
Lamivudine—NME1—Arf6 trafficking events—CTNNB1—sarcoma	0.00018	0.00858	CbGpPWpGaD
Lamivudine—ABCG2—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.000178	0.00845	CbGpPWpGaD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CTNNB1—sarcoma	0.000177	0.00844	CbGpPWpGaD
Lamivudine—DCK—testis—sarcoma	0.000177	0.00438	CbGeAlD
Lamivudine—ABCC3—testis—sarcoma	0.000169	0.00419	CbGeAlD
Lamivudine—ABCC4—tendon—sarcoma	0.000169	0.00418	CbGeAlD
Lamivudine—DCK—liver—sarcoma	0.000167	0.00414	CbGeAlD
Lamivudine—ABCC1—cardiac atrium—sarcoma	0.000165	0.00409	CbGeAlD
Lamivudine—ABCG2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000164	0.00783	CbGpPWpGaD
Lamivudine—ABCC1—uterus—sarcoma	0.000164	0.00407	CbGeAlD
Lamivudine—ABCC4—bone marrow—sarcoma	0.000163	0.00405	CbGeAlD
Lamivudine—ABCC2—tendon—sarcoma	0.000163	0.00405	CbGeAlD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—SRC—sarcoma	0.00016	0.00763	CbGpPWpGaD
Lamivudine—ABCC3—liver—sarcoma	0.00016	0.00396	CbGeAlD
Lamivudine—ABCC4—Platelet degranulation—VEGFC—sarcoma	0.000153	0.00727	CbGpPWpGaD
Lamivudine—ABCC2—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000149	0.00712	CbGpPWpGaD
Lamivudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.000145	0.00693	CbGpPWpGaD
Lamivudine—SLC22A3—testis—sarcoma	0.000144	0.00357	CbGeAlD
Lamivudine—ABCC1—tendon—sarcoma	0.000144	0.00356	CbGeAlD
Lamivudine—SLC22A1—liver—sarcoma	0.000142	0.00353	CbGeAlD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—sarcoma	0.00014	0.00669	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00014	0.00665	CbGpPWpGaD
Lamivudine—ABCC4—testis—sarcoma	0.00014	0.00346	CbGeAlD
Lamivudine—SLC22A3—liver—sarcoma	0.000136	0.00338	CbGeAlD
Lamivudine—ABCG2—uterus—sarcoma	0.000136	0.00337	CbGeAlD
Lamivudine—ABCC2—testis—sarcoma	0.000135	0.00335	CbGeAlD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000133	0.00631	CbGpPWpGaD
Lamivudine—ABCC4—liver—sarcoma	0.000132	0.00327	CbGeAlD
Lamivudine—DCK—lymph node—sarcoma	0.000128	0.00318	CbGeAlD
Lamivudine—ABCC2—liver—sarcoma	0.000128	0.00317	CbGeAlD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—MYC—sarcoma	0.000127	0.00605	CbGpPWpGaD
Lamivudine—ABCC3—lymph node—sarcoma	0.000123	0.00304	CbGeAlD
Lamivudine—ABCC1—testis—sarcoma	0.000119	0.00295	CbGeAlD
Lamivudine—ABCG2—bone marrow—sarcoma	0.000115	0.00286	CbGeAlD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—sarcoma	0.000113	0.00537	CbGpPWpGaD
Lamivudine—ABCC1—liver—sarcoma	0.000113	0.00279	CbGeAlD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000111	0.00531	CbGpPWpGaD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—TP53—sarcoma	0.000104	0.00497	CbGpPWpGaD
Lamivudine—SLC22A3—lymph node—sarcoma	0.000104	0.00259	CbGeAlD
Lamivudine—ABCB1—myometrium—sarcoma	0.000103	0.00256	CbGeAlD
Lamivudine—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000102	0.00488	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—VEGFA—sarcoma	0.000102	0.00486	CbGpPWpGaD
Lamivudine—ABCC4—lymph node—sarcoma	0.000101	0.00251	CbGeAlD
Lamivudine—ABCB1—embryo—sarcoma	9.93e-05	0.00246	CbGeAlD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	9.86e-05	0.0047	CbGpPWpGaD
Lamivudine—ABCG2—testis—sarcoma	9.85e-05	0.00244	CbGeAlD
Lamivudine—ABCC2—lymph node—sarcoma	9.79e-05	0.00243	CbGeAlD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—MYC—sarcoma	9.64e-05	0.00459	CbGpPWpGaD
Lamivudine—ABCB1—seminal vesicle—sarcoma	9.33e-05	0.00231	CbGeAlD
Lamivudine—ABCG2—liver—sarcoma	9.32e-05	0.00231	CbGeAlD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	9.23e-05	0.00439	CbGpPWpGaD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	9.08e-05	0.00433	CbGpPWpGaD
Lamivudine—ABCB1—hematopoietic system—sarcoma	8.87e-05	0.0022	CbGeAlD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	8.76e-05	0.00417	CbGpPWpGaD
Lamivudine—ABCC1—lymph node—sarcoma	8.63e-05	0.00214	CbGeAlD
Lamivudine—PGK1—Disease—TLE1—sarcoma	8.31e-05	0.00396	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	8.23e-05	0.00392	CbGpPWpGaD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—TP53—sarcoma	7.91e-05	0.00377	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	7.63e-05	0.00363	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	7.55e-05	0.0036	CbGpPWpGaD
Lamivudine—PGK1—Disease—NPM1—sarcoma	7.49e-05	0.00357	CbGpPWpGaD
Lamivudine—Dysphagia—Epirubicin—sarcoma	7.42e-05	0.00111	CcSEcCtD
Lamivudine—Pruritus—Thiotepa—sarcoma	7.41e-05	0.0011	CcSEcCtD
Lamivudine—Gastrointestinal pain—Mitoxantrone—sarcoma	7.4e-05	0.0011	CcSEcCtD
Lamivudine—Dehydration—Doxorubicin—sarcoma	7.38e-05	0.0011	CcSEcCtD
Lamivudine—Thrombocytopenia—Etoposide—sarcoma	7.37e-05	0.0011	CcSEcCtD
Lamivudine—Abdominal pain—Vincristine—sarcoma	7.34e-05	0.00109	CcSEcCtD
Lamivudine—Body temperature increased—Vincristine—sarcoma	7.34e-05	0.00109	CcSEcCtD
Lamivudine—Liver function test abnormal—Doxorubicin—sarcoma	7.33e-05	0.00109	CcSEcCtD
Lamivudine—Skin disorder—Etoposide—sarcoma	7.31e-05	0.00109	CcSEcCtD
Lamivudine—Hyperhidrosis—Etoposide—sarcoma	7.27e-05	0.00108	CcSEcCtD
Lamivudine—Pancreatitis—Epirubicin—sarcoma	7.27e-05	0.00108	CcSEcCtD
Lamivudine—Abdominal pain upper—Doxorubicin—sarcoma	7.25e-05	0.00108	CcSEcCtD
Lamivudine—Urticaria—Mitoxantrone—sarcoma	7.19e-05	0.00107	CcSEcCtD
Lamivudine—Anorexia—Etoposide—sarcoma	7.17e-05	0.00107	CcSEcCtD
Lamivudine—Diarrhoea—Thiotepa—sarcoma	7.17e-05	0.00107	CcSEcCtD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	7.17e-05	0.00341	CbGpPWpGaD
Lamivudine—Body temperature increased—Mitoxantrone—sarcoma	7.15e-05	0.00107	CcSEcCtD
Lamivudine—Abdominal pain—Mitoxantrone—sarcoma	7.15e-05	0.00107	CcSEcCtD
Lamivudine—Aspartate aminotransferase increased—Doxorubicin—sarcoma	7.15e-05	0.00107	CcSEcCtD
Lamivudine—ABCG2—lymph node—sarcoma	7.14e-05	0.00177	CbGeAlD
Lamivudine—Bronchitis—Epirubicin—sarcoma	7.13e-05	0.00106	CcSEcCtD
Lamivudine—Diarrhoea—Dactinomycin—sarcoma	7.11e-05	0.00106	CcSEcCtD
Lamivudine—Nasopharyngitis—Doxorubicin—sarcoma	7.1e-05	0.00106	CcSEcCtD
Lamivudine—Pancytopenia—Epirubicin—sarcoma	7.04e-05	0.00105	CcSEcCtD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	7.04e-05	0.00335	CbGpPWpGaD
Lamivudine—Hypotension—Etoposide—sarcoma	7.03e-05	0.00105	CcSEcCtD
Lamivudine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.03e-05	0.00335	CbGpPWpGaD
Lamivudine—Alanine aminotransferase increased—Doxorubicin—sarcoma	7e-05	0.00104	CcSEcCtD
Lamivudine—Muscular weakness—Doxorubicin—sarcoma	7e-05	0.00104	CcSEcCtD
Lamivudine—Dysuria—Epirubicin—sarcoma	6.94e-05	0.00103	CcSEcCtD
Lamivudine—Neutropenia—Epirubicin—sarcoma	6.94e-05	0.00103	CcSEcCtD
Lamivudine—Dizziness—Thiotepa—sarcoma	6.93e-05	0.00103	CcSEcCtD
Lamivudine—Abdominal distension—Doxorubicin—sarcoma	6.91e-05	0.00103	CcSEcCtD
Lamivudine—Influenza—Doxorubicin—sarcoma	6.86e-05	0.00102	CcSEcCtD
Lamivudine—Dysphagia—Doxorubicin—sarcoma	6.86e-05	0.00102	CcSEcCtD
Lamivudine—Pollakiuria—Epirubicin—sarcoma	6.85e-05	0.00102	CcSEcCtD
Lamivudine—Hypersensitivity—Vincristine—sarcoma	6.84e-05	0.00102	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	6.81e-05	0.00324	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—VEGFC—sarcoma	6.77e-05	0.00323	CbGpPWpGaD
Lamivudine—Paraesthesia—Etoposide—sarcoma	6.76e-05	0.00101	CcSEcCtD
Lamivudine—Pancreatitis—Doxorubicin—sarcoma	6.73e-05	0.001	CcSEcCtD
Lamivudine—Dyspnoea—Etoposide—sarcoma	6.71e-05	0.001	CcSEcCtD
Lamivudine—ABCB1—uterus—sarcoma	6.7e-05	0.00166	CbGeAlD
Lamivudine—Hyperglycaemia—Epirubicin—sarcoma	6.69e-05	0.000997	CcSEcCtD
Lamivudine—Somnolence—Etoposide—sarcoma	6.69e-05	0.000997	CcSEcCtD
Lamivudine—PCYT2—Metabolism—ENO2—sarcoma	6.67e-05	0.00318	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—ENO2—sarcoma	6.67e-05	0.00318	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—ENO2—sarcoma	6.67e-05	0.00318	CbGpPWpGaD
Lamivudine—Hypersensitivity—Mitoxantrone—sarcoma	6.67e-05	0.000994	CcSEcCtD
Lamivudine—Asthenia—Vincristine—sarcoma	6.66e-05	0.000993	CcSEcCtD
Lamivudine—Vomiting—Thiotepa—sarcoma	6.66e-05	0.000993	CcSEcCtD
Lamivudine—PCYT2—Metabolism—HBA1—sarcoma	6.63e-05	0.00316	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—HBA1—sarcoma	6.63e-05	0.00316	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—HBA1—sarcoma	6.63e-05	0.00316	CbGpPWpGaD
Lamivudine—Vomiting—Dactinomycin—sarcoma	6.61e-05	0.000985	CcSEcCtD
Lamivudine—Rash—Thiotepa—sarcoma	6.61e-05	0.000985	CcSEcCtD
Lamivudine—Bronchitis—Doxorubicin—sarcoma	6.6e-05	0.000984	CcSEcCtD
Lamivudine—Dermatitis—Thiotepa—sarcoma	6.6e-05	0.000984	CcSEcCtD
Lamivudine—Headache—Thiotepa—sarcoma	6.56e-05	0.000978	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Epirubicin—sarcoma	6.56e-05	0.000977	CcSEcCtD
Lamivudine—Rash—Dactinomycin—sarcoma	6.56e-05	0.000977	CcSEcCtD
Lamivudine—Decreased appetite—Etoposide—sarcoma	6.54e-05	0.000975	CcSEcCtD
Lamivudine—Pancytopenia—Doxorubicin—sarcoma	6.52e-05	0.000972	CcSEcCtD
Lamivudine—Renal failure—Epirubicin—sarcoma	6.5e-05	0.000969	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Etoposide—sarcoma	6.5e-05	0.000968	CcSEcCtD
Lamivudine—PGK1—Disease—ENO2—sarcoma	6.49e-05	0.00309	CbGpPWpGaD
Lamivudine—Asthenia—Mitoxantrone—sarcoma	6.49e-05	0.000968	CcSEcCtD
Lamivudine—Fatigue—Etoposide—sarcoma	6.49e-05	0.000967	CcSEcCtD
Lamivudine—Neuropathy peripheral—Epirubicin—sarcoma	6.48e-05	0.000966	CcSEcCtD
Lamivudine—Jaundice—Epirubicin—sarcoma	6.45e-05	0.000961	CcSEcCtD
Lamivudine—Stomatitis—Epirubicin—sarcoma	6.45e-05	0.000961	CcSEcCtD
Lamivudine—Constipation—Etoposide—sarcoma	6.43e-05	0.000959	CcSEcCtD
Lamivudine—Pain—Etoposide—sarcoma	6.43e-05	0.000959	CcSEcCtD
Lamivudine—Neutropenia—Doxorubicin—sarcoma	6.42e-05	0.000957	CcSEcCtD
Lamivudine—Dysuria—Doxorubicin—sarcoma	6.42e-05	0.000957	CcSEcCtD
Lamivudine—Diarrhoea—Vincristine—sarcoma	6.36e-05	0.000947	CcSEcCtD
Lamivudine—Sweating—Epirubicin—sarcoma	6.34e-05	0.000945	CcSEcCtD
Lamivudine—Pollakiuria—Doxorubicin—sarcoma	6.34e-05	0.000945	CcSEcCtD
Lamivudine—ABCC3—Fluoropyrimidine Activity—TP53—sarcoma	6.33e-05	0.00302	CbGpPWpGaD
Lamivudine—Hepatobiliary disease—Epirubicin—sarcoma	6.25e-05	0.000932	CcSEcCtD
Lamivudine—ABCB1—lymphoid tissue—sarcoma	6.24e-05	0.00155	CbGeAlD
Lamivudine—Epistaxis—Epirubicin—sarcoma	6.24e-05	0.00093	CcSEcCtD
Lamivudine—Nausea—Thiotepa—sarcoma	6.22e-05	0.000928	CcSEcCtD
Lamivudine—Sinusitis—Epirubicin—sarcoma	6.2e-05	0.000925	CcSEcCtD
Lamivudine—Feeling abnormal—Etoposide—sarcoma	6.2e-05	0.000924	CcSEcCtD
Lamivudine—Hyperglycaemia—Doxorubicin—sarcoma	6.19e-05	0.000923	CcSEcCtD
Lamivudine—Diarrhoea—Mitoxantrone—sarcoma	6.19e-05	0.000923	CcSEcCtD
Lamivudine—Nausea—Dactinomycin—sarcoma	6.18e-05	0.000921	CcSEcCtD
Lamivudine—Agranulocytosis—Epirubicin—sarcoma	6.17e-05	0.00092	CcSEcCtD
Lamivudine—Gastrointestinal pain—Etoposide—sarcoma	6.15e-05	0.000917	CcSEcCtD
Lamivudine—Dizziness—Vincristine—sarcoma	6.14e-05	0.000916	CcSEcCtD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—MYC—sarcoma	6.12e-05	0.00291	CbGpPWpGaD
Lamivudine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	6.07e-05	0.000904	CcSEcCtD
Lamivudine—Renal failure—Doxorubicin—sarcoma	6.02e-05	0.000897	CcSEcCtD
Lamivudine—Neuropathy peripheral—Doxorubicin—sarcoma	6e-05	0.000894	CcSEcCtD
Lamivudine—Urticaria—Etoposide—sarcoma	5.98e-05	0.000891	CcSEcCtD
Lamivudine—Jaundice—Doxorubicin—sarcoma	5.96e-05	0.000889	CcSEcCtD
Lamivudine—Stomatitis—Doxorubicin—sarcoma	5.96e-05	0.000889	CcSEcCtD
Lamivudine—ABCC4—Fluoropyrimidine Activity—TP53—sarcoma	5.95e-05	0.00284	CbGpPWpGaD
Lamivudine—Rhinitis—Epirubicin—sarcoma	5.95e-05	0.000887	CcSEcCtD
Lamivudine—Abdominal pain—Etoposide—sarcoma	5.95e-05	0.000887	CcSEcCtD
Lamivudine—Body temperature increased—Etoposide—sarcoma	5.95e-05	0.000887	CcSEcCtD
Lamivudine—Hepatitis—Epirubicin—sarcoma	5.94e-05	0.000885	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	5.93e-05	0.00282	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	5.92e-05	0.00282	CbGpPWpGaD
Lamivudine—Hypoaesthesia—Epirubicin—sarcoma	5.91e-05	0.000881	CcSEcCtD
Lamivudine—Vomiting—Vincristine—sarcoma	5.91e-05	0.00088	CcSEcCtD
Lamivudine—Pharyngitis—Epirubicin—sarcoma	5.89e-05	0.000878	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	5.87e-05	0.0028	CbGpPWpGaD
Lamivudine—Sweating—Doxorubicin—sarcoma	5.87e-05	0.000874	CcSEcCtD
Lamivudine—Rash—Vincristine—sarcoma	5.86e-05	0.000873	CcSEcCtD
Lamivudine—Dermatitis—Vincristine—sarcoma	5.85e-05	0.000872	CcSEcCtD
Lamivudine—Connective tissue disorder—Epirubicin—sarcoma	5.83e-05	0.00087	CcSEcCtD
Lamivudine—Headache—Vincristine—sarcoma	5.82e-05	0.000867	CcSEcCtD
Lamivudine—Hepatobiliary disease—Doxorubicin—sarcoma	5.79e-05	0.000863	CcSEcCtD
Lamivudine—Epistaxis—Doxorubicin—sarcoma	5.77e-05	0.00086	CcSEcCtD
Lamivudine—Vomiting—Mitoxantrone—sarcoma	5.75e-05	0.000857	CcSEcCtD
Lamivudine—Sinusitis—Doxorubicin—sarcoma	5.74e-05	0.000856	CcSEcCtD
Lamivudine—Agranulocytosis—Doxorubicin—sarcoma	5.71e-05	0.000851	CcSEcCtD
Lamivudine—Rash—Mitoxantrone—sarcoma	5.7e-05	0.00085	CcSEcCtD
Lamivudine—Dermatitis—Mitoxantrone—sarcoma	5.7e-05	0.000849	CcSEcCtD
Lamivudine—ABCB1—bone marrow—sarcoma	5.68e-05	0.00141	CbGeAlD
Lamivudine—Headache—Mitoxantrone—sarcoma	5.67e-05	0.000845	CcSEcCtD
Lamivudine—NT5C—Metabolism—PLCG1—sarcoma	5.66e-05	0.00269	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—PLCG1—sarcoma	5.66e-05	0.00269	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—PLCG1—sarcoma	5.66e-05	0.00269	CbGpPWpGaD
Lamivudine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	5.64e-05	0.00269	CbGpPWpGaD
Lamivudine—Erythema multiforme—Epirubicin—sarcoma	5.61e-05	0.000837	CcSEcCtD
Lamivudine—Hypersensitivity—Etoposide—sarcoma	5.54e-05	0.000826	CcSEcCtD
Lamivudine—Nausea—Vincristine—sarcoma	5.52e-05	0.000822	CcSEcCtD
Lamivudine—PGK1—Disease—PLCG1—sarcoma	5.51e-05	0.00262	CbGpPWpGaD
Lamivudine—Rhinitis—Doxorubicin—sarcoma	5.51e-05	0.000821	CcSEcCtD
Lamivudine—Hepatitis—Doxorubicin—sarcoma	5.49e-05	0.000819	CcSEcCtD
Lamivudine—Hypoaesthesia—Doxorubicin—sarcoma	5.47e-05	0.000815	CcSEcCtD
Lamivudine—Pharyngitis—Doxorubicin—sarcoma	5.45e-05	0.000813	CcSEcCtD
Lamivudine—PGK1—Metabolism—ENO2—sarcoma	5.44e-05	0.00259	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—HBA1—sarcoma	5.4e-05	0.00257	CbGpPWpGaD
Lamivudine—Asthenia—Etoposide—sarcoma	5.4e-05	0.000805	CcSEcCtD
Lamivudine—Connective tissue disorder—Doxorubicin—sarcoma	5.4e-05	0.000805	CcSEcCtD
Lamivudine—Nausea—Mitoxantrone—sarcoma	5.37e-05	0.000801	CcSEcCtD
Lamivudine—Immune system disorder—Epirubicin—sarcoma	5.36e-05	0.000799	CcSEcCtD
Lamivudine—Mediastinal disorder—Epirubicin—sarcoma	5.35e-05	0.000798	CcSEcCtD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	5.33e-05	0.00254	CbGpPWpGaD
Lamivudine—Chills—Epirubicin—sarcoma	5.33e-05	0.000794	CcSEcCtD
Lamivudine—Pruritus—Etoposide—sarcoma	5.32e-05	0.000794	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	5.31e-05	0.00253	CbGpPWpGaD
Lamivudine—PGK1—Disease—CXCR4—sarcoma	5.29e-05	0.00252	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	5.28e-05	0.00252	CbGpPWpGaD
Lamivudine—Alopecia—Epirubicin—sarcoma	5.25e-05	0.000782	CcSEcCtD
Lamivudine—Erythema multiforme—Doxorubicin—sarcoma	5.19e-05	0.000774	CcSEcCtD
Lamivudine—Erythema—Epirubicin—sarcoma	5.17e-05	0.00077	CcSEcCtD
Lamivudine—Malnutrition—Epirubicin—sarcoma	5.17e-05	0.00077	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.17e-05	0.00246	CbGpPWpGaD
Lamivudine—Diarrhoea—Etoposide—sarcoma	5.15e-05	0.000767	CcSEcCtD
Lamivudine—Flatulence—Epirubicin—sarcoma	5.09e-05	0.000759	CcSEcCtD
Lamivudine—Tension—Epirubicin—sarcoma	5.07e-05	0.000756	CcSEcCtD
Lamivudine—Dysgeusia—Epirubicin—sarcoma	5.06e-05	0.000754	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—ENO2—sarcoma	5.05e-05	0.00241	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—TP53—sarcoma	5.02e-05	0.00239	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—HBA1—sarcoma	5.02e-05	0.00239	CbGpPWpGaD
Lamivudine—Nervousness—Epirubicin—sarcoma	5.02e-05	0.000748	CcSEcCtD
Lamivudine—Back pain—Epirubicin—sarcoma	5e-05	0.000745	CcSEcCtD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	4.99e-05	0.00238	CbGpPWpGaD
Lamivudine—Dizziness—Etoposide—sarcoma	4.98e-05	0.000742	CcSEcCtD
Lamivudine—Muscle spasms—Epirubicin—sarcoma	4.97e-05	0.000741	CcSEcCtD
Lamivudine—Immune system disorder—Doxorubicin—sarcoma	4.96e-05	0.00074	CcSEcCtD
Lamivudine—Mediastinal disorder—Doxorubicin—sarcoma	4.95e-05	0.000738	CcSEcCtD
Lamivudine—Chills—Doxorubicin—sarcoma	4.93e-05	0.000735	CcSEcCtD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	4.91e-05	0.00234	CbGpPWpGaD
Lamivudine—ABCB1—testis—sarcoma	4.86e-05	0.00121	CbGeAlD
Lamivudine—Alopecia—Doxorubicin—sarcoma	4.85e-05	0.000724	CcSEcCtD
Lamivudine—Ill-defined disorder—Epirubicin—sarcoma	4.8e-05	0.000715	CcSEcCtD
Lamivudine—Vomiting—Etoposide—sarcoma	4.78e-05	0.000713	CcSEcCtD
Lamivudine—Malnutrition—Doxorubicin—sarcoma	4.78e-05	0.000713	CcSEcCtD
Lamivudine—Erythema—Doxorubicin—sarcoma	4.78e-05	0.000713	CcSEcCtD
Lamivudine—Anaemia—Epirubicin—sarcoma	4.78e-05	0.000712	CcSEcCtD
Lamivudine—ABCC4—Hemostasis—TEK—sarcoma	4.76e-05	0.00227	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.75e-05	0.00226	CbGpPWpGaD
Lamivudine—Rash—Etoposide—sarcoma	4.74e-05	0.000707	CcSEcCtD
Lamivudine—Dermatitis—Etoposide—sarcoma	4.74e-05	0.000707	CcSEcCtD
Lamivudine—Headache—Etoposide—sarcoma	4.71e-05	0.000703	CcSEcCtD
Lamivudine—Flatulence—Doxorubicin—sarcoma	4.71e-05	0.000702	CcSEcCtD
Lamivudine—Tension—Doxorubicin—sarcoma	4.69e-05	0.0007	CcSEcCtD
Lamivudine—Dysgeusia—Doxorubicin—sarcoma	4.68e-05	0.000698	CcSEcCtD
Lamivudine—Malaise—Epirubicin—sarcoma	4.66e-05	0.000695	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	4.65e-05	0.00221	CbGpPWpGaD
Lamivudine—Nervousness—Doxorubicin—sarcoma	4.64e-05	0.000692	CcSEcCtD
Lamivudine—Vertigo—Epirubicin—sarcoma	4.64e-05	0.000692	CcSEcCtD
Lamivudine—Syncope—Epirubicin—sarcoma	4.63e-05	0.000691	CcSEcCtD
Lamivudine—Leukopenia—Epirubicin—sarcoma	4.63e-05	0.00069	CcSEcCtD
Lamivudine—Back pain—Doxorubicin—sarcoma	4.63e-05	0.00069	CcSEcCtD
Lamivudine—NME2—Metabolism—ENO2—sarcoma	4.62e-05	0.0022	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—PLCG1—sarcoma	4.61e-05	0.0022	CbGpPWpGaD
Lamivudine—Muscle spasms—Doxorubicin—sarcoma	4.6e-05	0.000685	CcSEcCtD
Lamivudine—ABCB1—liver—sarcoma	4.59e-05	0.00114	CbGeAlD
Lamivudine—NME2—Metabolism—HBA1—sarcoma	4.59e-05	0.00219	CbGpPWpGaD
Lamivudine—Loss of consciousness—Epirubicin—sarcoma	4.54e-05	0.000677	CcSEcCtD
Lamivudine—Cough—Epirubicin—sarcoma	4.51e-05	0.000672	CcSEcCtD
Lamivudine—Convulsion—Epirubicin—sarcoma	4.48e-05	0.000667	CcSEcCtD
Lamivudine—Nausea—Etoposide—sarcoma	4.47e-05	0.000666	CcSEcCtD
Lamivudine—Ill-defined disorder—Doxorubicin—sarcoma	4.44e-05	0.000661	CcSEcCtD
Lamivudine—Anaemia—Doxorubicin—sarcoma	4.42e-05	0.000659	CcSEcCtD
Lamivudine—Chest pain—Epirubicin—sarcoma	4.4e-05	0.000656	CcSEcCtD
Lamivudine—Arthralgia—Epirubicin—sarcoma	4.4e-05	0.000656	CcSEcCtD
Lamivudine—Myalgia—Epirubicin—sarcoma	4.4e-05	0.000656	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.39e-05	0.00209	CbGpPWpGaD
Lamivudine—Anxiety—Epirubicin—sarcoma	4.38e-05	0.000654	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.37e-05	0.000651	CcSEcCtD
Lamivudine—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	4.37e-05	0.00208	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—ANGPT2—sarcoma	4.35e-05	0.00207	CbGpPWpGaD
Lamivudine—Discomfort—Epirubicin—sarcoma	4.35e-05	0.000648	CcSEcCtD
Lamivudine—Malaise—Doxorubicin—sarcoma	4.31e-05	0.000643	CcSEcCtD
Lamivudine—Dry mouth—Epirubicin—sarcoma	4.3e-05	0.000641	CcSEcCtD
Lamivudine—Vertigo—Doxorubicin—sarcoma	4.3e-05	0.00064	CcSEcCtD
Lamivudine—Syncope—Doxorubicin—sarcoma	4.29e-05	0.000639	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—PLCG1—sarcoma	4.29e-05	0.00204	CbGpPWpGaD
Lamivudine—Leukopenia—Doxorubicin—sarcoma	4.28e-05	0.000638	CcSEcCtD
Lamivudine—Confusional state—Epirubicin—sarcoma	4.25e-05	0.000634	CcSEcCtD
Lamivudine—Oedema—Epirubicin—sarcoma	4.22e-05	0.000629	CcSEcCtD
Lamivudine—Anaphylactic shock—Epirubicin—sarcoma	4.22e-05	0.000629	CcSEcCtD
Lamivudine—Loss of consciousness—Doxorubicin—sarcoma	4.2e-05	0.000627	CcSEcCtD
Lamivudine—Infection—Epirubicin—sarcoma	4.19e-05	0.000625	CcSEcCtD
Lamivudine—Cough—Doxorubicin—sarcoma	4.17e-05	0.000622	CcSEcCtD
Lamivudine—Shock—Epirubicin—sarcoma	4.15e-05	0.000619	CcSEcCtD
Lamivudine—Convulsion—Doxorubicin—sarcoma	4.14e-05	0.000618	CcSEcCtD
Lamivudine—Nervous system disorder—Epirubicin—sarcoma	4.14e-05	0.000617	CcSEcCtD
Lamivudine—Thrombocytopenia—Epirubicin—sarcoma	4.13e-05	0.000616	CcSEcCtD
Lamivudine—Skin disorder—Epirubicin—sarcoma	4.1e-05	0.000611	CcSEcCtD
Lamivudine—Hyperhidrosis—Epirubicin—sarcoma	4.08e-05	0.000608	CcSEcCtD
Lamivudine—Arthralgia—Doxorubicin—sarcoma	4.07e-05	0.000607	CcSEcCtD
Lamivudine—Chest pain—Doxorubicin—sarcoma	4.07e-05	0.000607	CcSEcCtD
Lamivudine—Myalgia—Doxorubicin—sarcoma	4.07e-05	0.000607	CcSEcCtD
Lamivudine—Anxiety—Doxorubicin—sarcoma	4.06e-05	0.000605	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.04e-05	0.000603	CcSEcCtD
Lamivudine—Discomfort—Doxorubicin—sarcoma	4.02e-05	0.0006	CcSEcCtD
Lamivudine—Anorexia—Epirubicin—sarcoma	4.02e-05	0.000599	CcSEcCtD
Lamivudine—Dry mouth—Doxorubicin—sarcoma	3.98e-05	0.000594	CcSEcCtD
Lamivudine—Hypotension—Epirubicin—sarcoma	3.94e-05	0.000588	CcSEcCtD
Lamivudine—Confusional state—Doxorubicin—sarcoma	3.94e-05	0.000587	CcSEcCtD
Lamivudine—NME2—Metabolism—PLCG1—sarcoma	3.92e-05	0.00187	CbGpPWpGaD
Lamivudine—PGK1—Disease—FOXO1—sarcoma	3.91e-05	0.00186	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	3.9e-05	0.00186	CbGpPWpGaD
Lamivudine—Oedema—Doxorubicin—sarcoma	3.9e-05	0.000582	CcSEcCtD
Lamivudine—Anaphylactic shock—Doxorubicin—sarcoma	3.9e-05	0.000582	CcSEcCtD
Lamivudine—PGK1—Disease—PDGFRB—sarcoma	3.9e-05	0.00186	CbGpPWpGaD
Lamivudine—ABCC4—Platelet degranulation—VEGFA—sarcoma	3.88e-05	0.00185	CbGpPWpGaD
Lamivudine—Infection—Doxorubicin—sarcoma	3.88e-05	0.000578	CcSEcCtD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	3.88e-05	0.00185	CbGpPWpGaD
Lamivudine—Musculoskeletal discomfort—Epirubicin—sarcoma	3.84e-05	0.000573	CcSEcCtD
Lamivudine—PGK1—Disease—PDGFRA—sarcoma	3.84e-05	0.00183	CbGpPWpGaD
Lamivudine—Shock—Doxorubicin—sarcoma	3.84e-05	0.000572	CcSEcCtD
Lamivudine—Nervous system disorder—Doxorubicin—sarcoma	3.83e-05	0.000571	CcSEcCtD
Lamivudine—Thrombocytopenia—Doxorubicin—sarcoma	3.82e-05	0.00057	CcSEcCtD
Lamivudine—Insomnia—Epirubicin—sarcoma	3.82e-05	0.000569	CcSEcCtD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	3.81e-05	0.00181	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	3.8e-05	0.00181	CbGpPWpGaD
Lamivudine—Skin disorder—Doxorubicin—sarcoma	3.79e-05	0.000565	CcSEcCtD
Lamivudine—Paraesthesia—Epirubicin—sarcoma	3.79e-05	0.000565	CcSEcCtD
Lamivudine—Hyperhidrosis—Doxorubicin—sarcoma	3.77e-05	0.000562	CcSEcCtD
Lamivudine—Dyspnoea—Epirubicin—sarcoma	3.76e-05	0.000561	CcSEcCtD
Lamivudine—Somnolence—Epirubicin—sarcoma	3.75e-05	0.000559	CcSEcCtD
Lamivudine—Anorexia—Doxorubicin—sarcoma	3.72e-05	0.000555	CcSEcCtD
Lamivudine—Dyspepsia—Epirubicin—sarcoma	3.71e-05	0.000553	CcSEcCtD
Lamivudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	3.7e-05	0.00176	CbGpPWpGaD
Lamivudine—Decreased appetite—Epirubicin—sarcoma	3.67e-05	0.000547	CcSEcCtD
Lamivudine—Hypotension—Doxorubicin—sarcoma	3.65e-05	0.000544	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Epirubicin—sarcoma	3.64e-05	0.000543	CcSEcCtD
Lamivudine—Fatigue—Epirubicin—sarcoma	3.64e-05	0.000542	CcSEcCtD
Lamivudine—Pain—Epirubicin—sarcoma	3.61e-05	0.000538	CcSEcCtD
Lamivudine—Constipation—Epirubicin—sarcoma	3.61e-05	0.000538	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.56e-05	0.00053	CcSEcCtD
Lamivudine—Insomnia—Doxorubicin—sarcoma	3.53e-05	0.000526	CcSEcCtD
Lamivudine—ABCB1—lymph node—sarcoma	3.52e-05	0.000873	CbGeAlD
Lamivudine—Paraesthesia—Doxorubicin—sarcoma	3.5e-05	0.000522	CcSEcCtD
Lamivudine—NME1—Metabolism—ENO2—sarcoma	3.5e-05	0.00167	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—VEGFC—sarcoma	3.49e-05	0.00166	CbGpPWpGaD
Lamivudine—NME1—Metabolism—HBA1—sarcoma	3.48e-05	0.00166	CbGpPWpGaD
Lamivudine—Dyspnoea—Doxorubicin—sarcoma	3.48e-05	0.000519	CcSEcCtD
Lamivudine—Feeling abnormal—Epirubicin—sarcoma	3.48e-05	0.000518	CcSEcCtD
Lamivudine—Somnolence—Doxorubicin—sarcoma	3.47e-05	0.000517	CcSEcCtD
Lamivudine—Gastrointestinal pain—Epirubicin—sarcoma	3.45e-05	0.000514	CcSEcCtD
Lamivudine—Dyspepsia—Doxorubicin—sarcoma	3.44e-05	0.000512	CcSEcCtD
Lamivudine—Decreased appetite—Doxorubicin—sarcoma	3.39e-05	0.000506	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Doxorubicin—sarcoma	3.37e-05	0.000502	CcSEcCtD
Lamivudine—Fatigue—Doxorubicin—sarcoma	3.36e-05	0.000502	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—PDGFRA—sarcoma	3.35e-05	0.0016	CbGpPWpGaD
Lamivudine—Urticaria—Epirubicin—sarcoma	3.35e-05	0.000499	CcSEcCtD
Lamivudine—Pain—Doxorubicin—sarcoma	3.34e-05	0.000497	CcSEcCtD
Lamivudine—Constipation—Doxorubicin—sarcoma	3.34e-05	0.000497	CcSEcCtD
Lamivudine—Abdominal pain—Epirubicin—sarcoma	3.33e-05	0.000497	CcSEcCtD
Lamivudine—Body temperature increased—Epirubicin—sarcoma	3.33e-05	0.000497	CcSEcCtD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.32e-05	0.00158	CbGpPWpGaD
Lamivudine—Feeling abnormal—Doxorubicin—sarcoma	3.22e-05	0.000479	CcSEcCtD
Lamivudine—Gastrointestinal pain—Doxorubicin—sarcoma	3.19e-05	0.000476	CcSEcCtD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	3.12e-05	0.00148	CbGpPWpGaD
Lamivudine—Hypersensitivity—Epirubicin—sarcoma	3.11e-05	0.000463	CcSEcCtD
Lamivudine—Urticaria—Doxorubicin—sarcoma	3.1e-05	0.000462	CcSEcCtD
Lamivudine—Abdominal pain—Doxorubicin—sarcoma	3.09e-05	0.00046	CcSEcCtD
Lamivudine—Body temperature increased—Doxorubicin—sarcoma	3.09e-05	0.00046	CcSEcCtD
Lamivudine—Asthenia—Epirubicin—sarcoma	3.03e-05	0.000451	CcSEcCtD
Lamivudine—Pruritus—Epirubicin—sarcoma	2.98e-05	0.000445	CcSEcCtD
Lamivudine—PGK1—Disease—KIT—sarcoma	2.98e-05	0.00142	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PLCG1—sarcoma	2.97e-05	0.00142	CbGpPWpGaD
Lamivudine—Diarrhoea—Epirubicin—sarcoma	2.89e-05	0.00043	CcSEcCtD
Lamivudine—Hypersensitivity—Doxorubicin—sarcoma	2.88e-05	0.000429	CcSEcCtD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	2.86e-05	0.00136	CbGpPWpGaD
Lamivudine—ABCC4—Ectoderm Differentiation—CTNNB1—sarcoma	2.85e-05	0.00136	CbGpPWpGaD
Lamivudine—PGK1—Disease—CREB1—sarcoma	2.83e-05	0.00135	CbGpPWpGaD
Lamivudine—Asthenia—Doxorubicin—sarcoma	2.8e-05	0.000417	CcSEcCtD
Lamivudine—Dizziness—Epirubicin—sarcoma	2.79e-05	0.000416	CcSEcCtD
Lamivudine—Pruritus—Doxorubicin—sarcoma	2.76e-05	0.000412	CcSEcCtD
Lamivudine—ABCC4—Hemostasis—PLCG1—sarcoma	2.74e-05	0.00131	CbGpPWpGaD
Lamivudine—Vomiting—Epirubicin—sarcoma	2.68e-05	0.0004	CcSEcCtD
Lamivudine—Diarrhoea—Doxorubicin—sarcoma	2.67e-05	0.000398	CcSEcCtD
Lamivudine—Rash—Epirubicin—sarcoma	2.66e-05	0.000396	CcSEcCtD
Lamivudine—Dermatitis—Epirubicin—sarcoma	2.66e-05	0.000396	CcSEcCtD
Lamivudine—Headache—Epirubicin—sarcoma	2.64e-05	0.000394	CcSEcCtD
Lamivudine—Dizziness—Doxorubicin—sarcoma	2.58e-05	0.000385	CcSEcCtD
Lamivudine—Nausea—Epirubicin—sarcoma	2.51e-05	0.000373	CcSEcCtD
Lamivudine—Vomiting—Doxorubicin—sarcoma	2.48e-05	0.00037	CcSEcCtD
Lamivudine—Rash—Doxorubicin—sarcoma	2.46e-05	0.000367	CcSEcCtD
Lamivudine—Dermatitis—Doxorubicin—sarcoma	2.46e-05	0.000366	CcSEcCtD
Lamivudine—Headache—Doxorubicin—sarcoma	2.45e-05	0.000364	CcSEcCtD
Lamivudine—DCK—Metabolism—ENO2—sarcoma	2.4e-05	0.00114	CbGpPWpGaD
Lamivudine—DCK—Metabolism—HBA1—sarcoma	2.39e-05	0.00114	CbGpPWpGaD
Lamivudine—PGK1—Disease—MDM2—sarcoma	2.35e-05	0.00112	CbGpPWpGaD
Lamivudine—Nausea—Doxorubicin—sarcoma	2.32e-05	0.000346	CcSEcCtD
Lamivudine—ABCC4—Ectoderm Differentiation—MYC—sarcoma	2.31e-05	0.0011	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—CREB1—sarcoma	2.15e-05	0.00103	CbGpPWpGaD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	2.1e-05	0.000998	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	2.05e-05	0.000978	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PLCG1—sarcoma	2.04e-05	0.000971	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—IL2—sarcoma	2.03e-05	0.000965	CbGpPWpGaD
Lamivudine—PGK1—Disease—CTNNB1—sarcoma	2.02e-05	0.000963	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—CREB1—sarcoma	2.01e-05	0.000956	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—IL2—sarcoma	1.83e-05	0.000871	CbGpPWpGaD
Lamivudine—PGK1—Disease—SRC—sarcoma	1.83e-05	0.000871	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	1.79e-05	0.000855	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—MDM2—sarcoma	1.78e-05	0.000849	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—SRC—sarcoma	1.77e-05	0.000842	CbGpPWpGaD
Lamivudine—PGK1—Disease—NRAS—sarcoma	1.76e-05	0.000838	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.72e-05	0.00082	CbGpPWpGaD
Lamivudine—ABCC1—Disease—TLE1—sarcoma	1.67e-05	0.000795	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—MDM2—sarcoma	1.66e-05	0.000791	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.65e-05	0.000788	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—CREB1—sarcoma	1.65e-05	0.000786	CbGpPWpGaD
Lamivudine—PGK1—Disease—MYC—sarcoma	1.64e-05	0.00078	CbGpPWpGaD
Lamivudine—PGK1—Disease—EGFR—sarcoma	1.6e-05	0.000763	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—VEGFA—sarcoma	1.55e-05	0.00074	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—CREB1—sarcoma	1.54e-05	0.000732	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ENO2—sarcoma	1.52e-05	0.000723	CbGpPWpGaD
Lamivudine—PGK1—Disease—KRAS—sarcoma	1.51e-05	0.000721	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—HBA1—sarcoma	1.51e-05	0.000718	CbGpPWpGaD
Lamivudine—ABCC1—Disease—NPM1—sarcoma	1.51e-05	0.000717	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ENO2—sarcoma	1.39e-05	0.000664	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—HBA1—sarcoma	1.39e-05	0.00066	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—MDM2—sarcoma	1.37e-05	0.00065	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ENO2—sarcoma	1.3e-05	0.000621	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PLCG1—sarcoma	1.29e-05	0.000613	CbGpPWpGaD
Lamivudine—PGK1—Disease—HRAS—sarcoma	1.29e-05	0.000613	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—MDM2—sarcoma	1.27e-05	0.000606	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.22e-05	0.000581	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PLCG1—sarcoma	1.18e-05	0.000564	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PLCG1—sarcoma	1.11e-05	0.000527	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ENO2—sarcoma	1.09e-05	0.00052	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—HBA1—sarcoma	1.09e-05	0.000517	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CXCR4—sarcoma	1.06e-05	0.000507	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—IL2—sarcoma	1.04e-05	0.000497	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.01e-05	0.000481	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—HRAS—sarcoma	9.78e-06	0.000466	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ENO2—sarcoma	9.62e-06	0.000458	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—HBA1—sarcoma	9.55e-06	0.000455	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ENO2—sarcoma	9.52e-06	0.000453	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—HBA1—sarcoma	9.46e-06	0.00045	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PLCG1—sarcoma	9.27e-06	0.000442	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—HRAS—sarcoma	9.11e-06	0.000434	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—SRC—sarcoma	9.11e-06	0.000434	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—VEGFA—sarcoma	8.87e-06	0.000423	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ENO2—sarcoma	8.87e-06	0.000422	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—HBA1—sarcoma	8.81e-06	0.00042	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	8.8e-06	0.000419	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	8.78e-06	0.000418	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—NRAS—sarcoma	8.76e-06	0.000417	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	8.71e-06	0.000415	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PLCG1—sarcoma	8.16e-06	0.000389	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PLCG1—sarcoma	8.07e-06	0.000385	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	7.87e-06	0.000375	CbGpPWpGaD
Lamivudine—ABCC1—Disease—FOXO1—sarcoma	7.86e-06	0.000374	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PDGFRB—sarcoma	7.84e-06	0.000373	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PDGFRA—sarcoma	7.72e-06	0.000368	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	7.67e-06	0.000365	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—KRAS—sarcoma	7.54e-06	0.000359	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PLCG1—sarcoma	7.53e-06	0.000358	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—HRAS—sarcoma	7.49e-06	0.000357	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.06e-06	0.000336	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—HRAS—sarcoma	6.98e-06	0.000333	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	6.9e-06	0.000329	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—sarcoma	6.7e-06	0.000319	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6.52e-06	0.00031	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—HRAS—sarcoma	6.41e-06	0.000305	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KIT—sarcoma	5.99e-06	0.000285	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.79e-06	0.000276	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CREB1—sarcoma	5.7e-06	0.000271	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ENO2—sarcoma	5.2e-06	0.000248	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—HBA1—sarcoma	5.17e-06	0.000246	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MDM2—sarcoma	4.71e-06	0.000224	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PLCG1—sarcoma	4.41e-06	0.00021	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CTNNB1—sarcoma	4.07e-06	0.000194	CbGpPWpGaD
Lamivudine—ABCC1—Disease—SRC—sarcoma	3.68e-06	0.000175	CbGpPWpGaD
Lamivudine—ABCC1—Disease—NRAS—sarcoma	3.54e-06	0.000168	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MYC—sarcoma	3.29e-06	0.000157	CbGpPWpGaD
Lamivudine—ABCC1—Disease—EGFR—sarcoma	3.22e-06	0.000153	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KRAS—sarcoma	3.04e-06	0.000145	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HRAS—sarcoma	2.59e-06	0.000123	CbGpPWpGaD
